1. Introduction of
Outlineprimary recovery
2. Fundamentals of Centrifugation
3. Different Centrifuges
4. Centrifugation Process Design
5. Ultra Scale-down of Centrifugation
6. Case Study 1: Rapid Evaluation of Solid
Liquid Operations
1
,Ultra scale-down of Centrifugation
1. What is ultra scale-down and why do it?
2. Ultra scale-down device and critical regime
analysis
3. Critical regime analysis for industrial scale
centrifuge
4. Ultra scale-down study to predict the performance
of industrial scale centrifuges
,1. What is ultra scale-down (USD)?
1.The ability to research at a small scale and
provide new insights into how a
bioprocessing material is impacted by the
process engineering environment
2. The ability to inform on how to scale up
and provide material representative of full
scale
, Why do it?
1.Test cells and product candidates for
“manufacturability”, early and at low cost
2. Address novel bioprocessing solutions,
early and at low cost
3. Resolve large-scale manufacturing
challenges, early and at low cost
4. Help meet regulatory challenges
5. Move with speed to manufacture when
clinical indications are positive
Outlineprimary recovery
2. Fundamentals of Centrifugation
3. Different Centrifuges
4. Centrifugation Process Design
5. Ultra Scale-down of Centrifugation
6. Case Study 1: Rapid Evaluation of Solid
Liquid Operations
1
,Ultra scale-down of Centrifugation
1. What is ultra scale-down and why do it?
2. Ultra scale-down device and critical regime
analysis
3. Critical regime analysis for industrial scale
centrifuge
4. Ultra scale-down study to predict the performance
of industrial scale centrifuges
,1. What is ultra scale-down (USD)?
1.The ability to research at a small scale and
provide new insights into how a
bioprocessing material is impacted by the
process engineering environment
2. The ability to inform on how to scale up
and provide material representative of full
scale
, Why do it?
1.Test cells and product candidates for
“manufacturability”, early and at low cost
2. Address novel bioprocessing solutions,
early and at low cost
3. Resolve large-scale manufacturing
challenges, early and at low cost
4. Help meet regulatory challenges
5. Move with speed to manufacture when
clinical indications are positive